Call Buying Activity Continues in BioCryst Pharma (BCRX), Targeting Upside in Shares Through July -Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
BioCryst Pharma (BCRX) Prices 18.7M Share Common Offering at $4.50/Sh; Announces Pricing of Pre-Funded Warrants Offering
May 28, 2020 5:51 AM EDTBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today the pricing of an underwritten public offering of 18,711,113 shares of its common stock, offered at a price to the public of $4.50 per share. In addition, and in lieu of common stock, BioCryst is offering to certain investors pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of... More
After-Hours Stock Movers 05/27: (PHAS) (SMTC) (TOL) Higher; (IOVA) (ARNA) (PLT) Lower (more...)
May 27, 2020 5:41 PM EDTToday's After-Hours Stock Movers:
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) 74.4% HIGHER; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).
Semtech (NASDAQ: SMTC) 13.6% HIGHER; reported Q1 EPS of $0.35, $0.03 better than the analyst estimate of $0.32. Revenue for the quarter came in at $132.7 million versus the consensus estimate of $129.28 million. Semtech sees Q2 2021 EPS of... More
BioCryst Pharma (BCRX) Commences Public Offering of Common Stock and Pre-Funded Warrants
May 27, 2020 4:08 PM EDTBioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced today that it is offering to sell $100 million of its common stock and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock in an underwritten public offering. As... More
